The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2024 | The prognostic value of 18FDG-PET/CT in patients with R/R multiple myeloma treated with CAR-T
Luis-Esteban Tamariz-Amador, MD, University Clinic of Navarra, Pamplona, Spain, discusses the findings of a study that aimed to assess the value of 18FDG-PET/CT for predicting relapse in patients with relapsed/refractory (R/R) multiple myeloma (MM) treated with CAR T-cell therapy. This method was able to detect the presence of extramedullary disease (EMD), paramedullary disease (PMD), and focal lesions (FL), and this could aid in identifying which patients are at greater risk of relapse. Dr Tamariz-Amador highlights the need to wait until three months post-CAR-T infusion for optimal response assessment. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
